Ebola Fever - Pipeline Insight, 2024

Ebola Fever - Pipeline Insight, 2024

DelveInsight’s, “Ebola Fever – Pipeline Insight, 2024,” report provides comprehensive insights about companies and pipeline drugs in the Ebola Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Ebola Fever Understanding

Ebola Fever: Overview

Ebola, also known as Ebola virus disease (EVD) or Ebola Fever (EF), is a viral Ebola Fever of humans and other primates caused by Ebolaviruses. Ebola is a serious and deadly virus transmitted by animals and humans. The Ebola virus belongs to the viral family Filoviridae. Ebola virus causes Ebola Fever or profuse bleeding inside and outside the body. Ebola is introduced into the human population through close contact with the blood, secretions, organs or other bodily fluids of infected animals such as fruit bats, chimpanzees, gorillas, monkeys, forest antelope or porcupines found ill or dead or in the rainforest. Ebola then spreads through human-to-human transmission via direct contact.

Symptoms

Symptoms may appear anywhere from 2 to 21 days after contact with the virus, with an average of 8 to 10 days. Symptoms of Ebola Fever include:

● Fever

● Weakness and fatigue

● Muscle pain

● Headache

● Sore throat

● Abdominal pain

● Vomiting and diarrhea

Diagnosis

Diagnosing specific Ebola Fever in the first few days of illness can be difficult because the initial signs and symptoms — high fever, muscle aches, headaches and extreme fatigue — are common to many other diseases. Confirmation that symptoms are caused by Ebola virus infection are made using the following diagnostic methods: antibody-capture enzyme-linked immunosorbent assay (ELISA), antigen-capture detection tests, serum neutralization test, reverse transcriptase polymerase chain reaction (RT-PCR) assay, electron microscopy, virus isolation by cell culture.

Treatment

Currently, there is no specific medical treatment for Ebola Fever. Supportive care measures may include: giving medications to maintain blood pressure, managing electrolyte balances, providing extra oxygen, if needed, providing intravenous and/or oral fluids to prevent dehydration. Individuals can take several precautions to protect against Ebola.

Ebola Fever Emerging Drugs Chapters

This segment of the Ebola Fever report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ebola Fever Emerging Drugs

• Ad5-EBOV: CanSino Biologics

Ad5-EBOV is an adenovirus type 5 vector-based Ebola virus disease vaccine that protects against Ebola by relying on the recombinant replication-defective human adenovirus type-5 vector immune response. Ad5-EBOV is manufactured as a lyophilized powder, which is highly stable and does not require storage at ultra-low temperatures. The recombinant Ebola virus vaccine (Ad5-EBOV), jointly developed by CanSinoBIO and the Beijing Institute of Biotechnology, Academy of Military Medical Sciences (BIB), has obtained approval only in China.

● Ad26.ZEBOV and Mvabea: Janssen Pharmaceuticals

The new Ebola prevention vaccine therapy consists of 2 components, Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo). Zabdeno is given first, and Mvabea is administered approximately 8-weeks later as a booster. These vaccines both use a viral vector approach, where a virus is genetically modified not to replicate but is used to express the target virus's key proteins safely. Currently it is under phase III stage of investigation by Janssen Pharmaceutical Companies, a part of Johnson & Johnson.

• INO4212: Inovio Pharmaceuticals

Inovio is well-positioned to execute on our overall development strategy in positioning INO-4212 as a viable stockpile vaccine. INO-4212 is a vaccine that has shown to be stable at room temperature for one year in the phase I clinical trials.

Further product details are provided in the report……..

Ebola Fever: Therapeutic Assessment

This segment of the report provides insights about the different Ebola Fever drugs segregated based on following parameters that define the scope of the report, such as:

● Major Players in Ebola Fever

There are various companies which are developing the therapies for Ebola Fever. The companies which have their Ebola Fever drug candidates in the mid to advanced stage, i.e. phase III and Phase I include, Jansen Pharmaceuticals and others.

Phases

DelveInsight’s report covers products under different phases of clinical development like

• Late-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

● Route of Administration

Ebola Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Intramuscular
• Intradermal

● Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Proteins
• Monoclonal antibodies

● Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ebola Fever: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ebola Fever therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ebola Fever drugs.

Report Highlights

● The companies and academics are working to assess challenges and seek opportunities that could influence Ebola Fever R&D. The therapies under development are focused on novel approaches to treat/improve Ebola Fever.

Ebola Fever Report Insights

• Ebola Fever Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ebola Fever Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Ebola Fever drugs?
• How many Ebola Fever drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ebola Fever?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ebola Fever therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ebola Fever and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Jansen Pharmaceuticals
• CanSino Biologics
• Galactica Biotech Ltd
• Gilead Sciences
• GlaxoSmithKline
• Greffex Inc
• Integrated Biotherapeutics Inc.
• Inovio Pharmaceuticals
• Merck & co.
• Johnson & Johnson
• Vaccibody AS
• Tiba Biotech LLC
• Yaso Therapeutics Inc

Key Products

• Ad26.ZEBOV and Mvabea
• GS5734
• Ad5-EBOV
• INO4212
• ABX544
• cAd3-EBO Z